Association of Hair Concentrations of Antiretrovirals with Virologic Outcomes Among People Living with HIV in Guangxi, China

References

• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA. 2018;320(4):379–396. doi:10.1001/jama.2018.8431
   PubMed Web of Science ®Google Scholar
• Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475–490. doi:10.2147/PPA.S192735
   PubMed Web of Science ®Google Scholar
• Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART adherence: update for HIV treatment and prevention. Curr HIV/AIDS Rep. 2014;11(4):423–433. doi:10.1007/s11904-014-0229-5
   PubMed Web of Science ®Google Scholar
• Zhang Q, Qiao S, Yang X, Li X. Antiretroviral concentration in hair as a measure for antiretroviral medication adherence: a systematic review of global literature. AIDS Behav. 2020;24(1):311–330. doi:10.1007/s10461-019-02460-5
   PubMed Web of Science ®Google Scholar
• Saberi P, Ming K, Legnitto D, Neilands TB, Gandhi M, Johnson MO. Novel methods to estimate antiretroviral adherence: protocol for a longitudinal study. Patient Prefer Adherence. 2018;12:1033–1042. doi:10.2147/PPA.S166380
   Web of Science ®Google Scholar
• Marzolini CTA, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71–75. doi:10.1097/00002030-200101050-00011
   PubMed Web of Science ®Google Scholar
• Mwasakifwa GE, Moore C, Carey D, et al. Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018;32(3):357–361. doi:10.1097/QAD.0000000000001688
   Web of Science ®Google Scholar
• Gandhi M, Bacchetti P, Spinelli MA, et al. Brief report: validation of a urine tenofovir immunoassay for adherence monitoring to PrEP and ART and establishing the cutoff for a point-of-care test. J Acquir Immune Defic Syndr. 2019;81(1):72–77. doi:10.1097/QAI.0000000000001971
   Web of Science ®Google Scholar
• Baxi SM, Liu A, Bacchetti P, et al. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015;68(1):13–20. doi:10.1097/QAI.0000000000000386
   PubMed Web of Science ®Google Scholar
• Frasca K, Morrow M, Coyle RP, et al. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. J Antimicrob Chemother. 2019;74(5):1395–1401. doi:10.1093/jac/dky559
   Web of Science ®Google Scholar
• Morrow M, MaWhinney S, Coyle RP, et al. Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV. J Infect Dis. 2019;220(4):635–642. doi:10.1093/infdis/jiz144
   PubMed Web of Science ®Google Scholar
• Tabb ZJ, Mmbaga BT, Gandhi M, et al. Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. AIDS. 2018;32(9):1115–1123. doi:10.1097/QAD.0000000000001788
   PubMed Web of Science ®Google Scholar
• Yan J, Liu J, Su B, et al. Lamivudine concentration in hair and prediction of virologic failure and drug resistance among HIV patients receiving free ART in China. PLoS One. 2016;11(4):e0154421. doi:10.1371/journal.pone.0154421
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42(8):1189–1196. doi:10.1086/501458
   PubMed Web of Science ®Google Scholar
• Gandhi M, Gandhi RT, Stefanescu A, et al. Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis. 2018;218(2):234–238. doi:10.1093/infdis/jiy011
   Web of Science ®Google Scholar
• Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59. doi:10.1007/s11904-018-0377-0
   PubMed Web of Science ®Google Scholar
• Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002;137(8):696–697. doi:10.7326/0003-4819-137-8-200210150-00016
   PubMed Web of Science ®Google Scholar
• Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66(3):311–315. doi:10.1097/QAI.0000000000000154
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li X, Qiao S, Yang X. Factors related to hair antiretroviral concentration: a systematic review of global literature. AIDS Rev. 2020;22(1):25–33. doi:10.24875/AIDSRev.19000122
   Web of Science ®Google Scholar
• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33(4):307–320. doi:10.1016/j.ijantimicag.2008.10.010
   PubMed Web of Science ®Google Scholar
• Chu L, Wu Y, Duan C, et al. Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1097-1098:54–63. doi:10.1016/j.jchromb.2018.08.031
   PubMed Web of Science ®Google Scholar
• Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(21):3401–3409. doi:10.1002/rcm.3750
   Web of Science ®Google Scholar
• Shah SA, Mullin R, Jones G, et al. Simultaneous analysis of antiretroviral drugs abacavir and tenofovir in human hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013;74:308–313. doi:10.1016/j.jpba.2012.10.023
   Web of Science ®Google Scholar
• Wu Y, Yang J, Duan C, et al. Simultaneous determination of antiretroviral drugs in human hair with liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1083:209–221. doi:10.1016/j.jchromb.2018.03.021
   PubMed Web of Science ®Google Scholar
• Bernard L, Peytavin G, Vuagnat A, de Truchis P, Perronne C. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy. The Lancet. 1998;352(9142):1757–1758. doi:10.1016/S0140-6736(05)79831-7
   Web of Science ®Google Scholar
• Bernard L, Vuagnat A, Peytavin G, et al. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med. 2002;137(8):656–659. doi:10.7326/0003-4819-137-8-200210150-00009
   PubMed Web of Science ®Google Scholar
• Duval X, Peytavin G, Breton G, et al. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS. 2007;21(1):106–108. doi:10.1097/QAD.0b013e3280118486
   Web of Science ®Google Scholar
• Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–1275. doi:10.1093/cid/cir131
   PubMed Web of Science ®Google Scholar
• van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333–339. doi:10.1097/QAI.0b013e31820dc0cc
   PubMed Web of Science ®Google Scholar
• Baxi SM, Greenblatt RM, Bacchetti P, et al. Nevirapine concentration in hair samples is a strong predictor of virologic suppression in a prospective cohort of HIV-infected patients. PLoS One. 2015;10(6):e0129100. doi:10.1371/journal.pone.0129100
   PubMed Web of Science ®Google Scholar
• Prasitsuebsai W, Kerr SJ, Truong KH, et al. Using lopinavir concentrations in hair samples to assess treatment outcomes on second-line regimens among Asian children. AIDS Res Hum Retroviruses. 2015;31(10):1009–1014. doi:10.1089/aid.2015.0111
   PubMed Web of Science ®Google Scholar
• Pintye J, Bacchetti P, Teeraananchai S, et al. Brief report: lopinavir hair concentrations are the strongest predictor of viremia in HIV-infected Asian children and adolescents on second-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;76(4):367–371. doi:10.1097/QAI.0000000000001527
   Web of Science ®Google Scholar
• Murnane PM, Bacchetti P, Currier JS, et al. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. AIDS. 2019;33(10):1657–1662. doi:10.1097/QAD.0000000000002237
   PubMed Web of Science ®Google Scholar
• Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23(4):471–478. doi:10.1097/QAD.0b013e328325a4a9
   PubMed Web of Science ®Google Scholar
• Yang X, Li X, Qiao S, Zhang Q, Shen Z, Zhou Y. Immunological and virologic outcomes of people living with HIV in Guangxi, China: 2012-2017. PLoS One. 2019;14(3):e0213205. doi:10.1371/journal.pone.0213205
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Comparing self-reported medication adherence measures with hair antiretroviral concentration among people living with HIV in Guangxi, China. AIDS Res Ther. 2020;17(1):8. doi:10.1186/s12981-020-00265-4
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China. Antivir Ther. 2020;25(3):143–149. doi:10.3851/IMP3360
   PubMed Web of Science ®Google Scholar
• Cooper GA, Kronstrand R, Kintz P, Society of Hair T. Society of hair testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218(1–3):20–24. doi:10.1016/j.forsciint.2011.10.024
   PubMed Web of Science ®Google Scholar
• Sachs H. Quality control by the society of hair testing. Forensic Sci Int. 1997;84(1–3):145–150. doi:10.1016/S0379-0738(96)02057-9
   PubMed Web of Science ®Google Scholar
• Yang H, Chu L, Wu Y, et al. LC-MS/MS quantification of nevirapine and its metabolites in hair for assessing long-term adherence. Molecules. 2020;25:23. doi:10.3390/molecules25235692
   Web of Science ®Google Scholar
• Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451–452. doi:10.1001/jama.2018.21167
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–318. doi:10.1007/s10461-012-0326-7
   PubMed Web of Science ®Google Scholar
• Koss CA, Natureeba P, Mwesigwa J, et al. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015;29(7):825–830. doi:10.1097/QAD.0000000000000619
   PubMed Web of Science ®Google Scholar
• Chawana TD, Gandhi M, Nathoo K, et al. Defining a cutoff for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment. J Acquir Immune Defic Syndr. 2017;76(1):55–59. doi:10.1097/QAI.0000000000001452
   PubMed Web of Science ®Google Scholar
• Cohan D, Natureeba P, Koss CA, et al. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015;29(2):183–191. doi:10.1097/QAD.0000000000000531
   PubMed Web of Science ®Google Scholar
• Ngara B, Zvada S, Chawana TD, Stray-Pedersen B, Nhachi CFB, Rusakaniko S. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents. BMC Pharmacol Toxicol. 2020;21(1):58. doi:10.1186/s40360-020-00437-y
   Web of Science ®Google Scholar